Drugs / PfSPZ (NF54) Challenge
PfSPZ (NF54) Challenge
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02773979 Comparator | Sep 2016 → Jan 2018 | Plasmodium falciparum malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PfSPZ (NF54) Challenge | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02773979 ↗ |
| Known as | PfSPZ | “PfSPZ-CVac combines 'PfSPZ Challenge', which consists of infectious Plasmodium falciparum sporozoites (PfSPZ), with concurrent antimalarial chemoprophylaxis.” PMID 34048504 ↗ May 2021 |
| Known as | PfSPZ Challenge | “PfSPZ-CVac combines 'PfSPZ Challenge', which consists of infectious Plasmodium falciparum sporozoites (PfSPZ), with concurrent antimalarial chemoprophylaxis.” PMID 34048504 ↗ May 2021 |
| Known as | Sanaria PfSPZ Challenge | “escalating doses of Sanaria PfSPZ Challenge administered by DVI on varying schedules” NCT02773979 ↗ |
| Modality | Vaccine | “PfSPZ Challenge vaccine” NCT02773979 ↗ |
| Route | Intravenous | “At 10 weeks after the third administration of study vaccine or placebo, all subjects within the three groups will receive the PfSPZ Challenge by direct venous injection” NCT02773979 ↗ |